There is now considerable preclinical evidence that glutamate acting via the NMDA receptor is involved in the transmission of nociceptive information and in the triggering mechanisms for hyperalgesia and allodynia. This evidence allows rational development of a new class of analgesic drugs that act as antagonists of the NMDA receptor, supported by emerging evidence with existing excitatory amino acid antagonists. Lweiterlesen